ClinicalTrials.gg

Program

chloroprocaine

Also written as “Chloroprocaine Ophthalmic Gel 3% (IHEEZO)”, “Chloroprocaine 1% Injectable Solution” and “Chloroprocaine 2% Injectable Solution”.

Its studies are mostly in Macular Degeneration · Hernia, Inguinal · Cataract, led by 2 companies.

Furthest: phase 4, since Feb 20, 20158 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sintetica60 open or runningphase 3since Feb 20, 2015Feb 20, 2015none ahead
Harrow21 open or runningphase 4since Jun 9, 2023Jun 9, 2023none ahead

Also a collaborator on its studies: cross-research-s-a and cross-s-a.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 20, 2015First study: phase 3 study in Axillary Nerve BlockNew to SinteticaSintetica · NCT02385097 · 211 enrolled · Switzerland
  2. Jun 2, 2015Phase 2 study in Short Duration Lower Limb Surgery Via Spinal AnaesthesiaSintetica · NCT02481505 · 45 enrolled · Italy
  3. Aug 29, 2016Phase 3 study in Unplanned Caesarean SectionSintetica · NCT02919072 · 16 enrolled · Belgium
  4. Mar 20, 2019Phase 2 study in Hernia, InguinalSintetica · NCT03918798 · 164 enrolled · Italy, Spain
  5. Dec 15, 2020Phase 3 study in CataractSintetica · NCT04685538 · 338 enrolled · Italy, Slovakia, Spain
  6. Jun 6, 2023Phase 3 study in Local AnestheticSintetica · NCT05926258 · 74 enrolled · Italy
  7. Jun 9, 2023Harrow's first study: phase 4 study in AntisepticNew to HarrowHarrow · NCT05934253 · 100 enrolled · United States
  8. Feb 25, 2026Phase 4 study in Macular DegenerationHarrow · NCT07456826 · 236 planned · United States

TargetBeta

“Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07456826Macular Degeneration · United States4By invitationHarrowAug 2026236
NCT05934253Antiseptic · United States4CompletedHarrowJan 15, 2024100
NCT05926258Local Anesthetic · Italy3CompletedSinteticaMar 13, 202574
NCT04685538Cataract · Italy, Slovakia, Spain3CompletedSinteticaMar 1, 2021338
NCT03918798Hernia, Inguinal · Italy, Spain2CompletedSinteticaOct 17, 2025164
NCT02919072Unplanned Caesarean Section · Belgium3TerminatedSinteticaJun 202116
NCT02481505Short Duration Lower Limb Surgery Via Spinal Anaesthesia · Italy2CompletedSinteticaNov 201545
NCT02385097Axillary Nerve Block · Switzerland3CompletedSinteticaMay 2017211

How it is read

Names in the registry

  • “Chloroprocaine Ophthalmic Gel 3% (IHEEZO)”, 1 entry
  • “Chloroprocaine 1% Injectable Solution”, 1 entry
  • “Chloroprocaine 2% Injectable Solution”, 1 entry
  • “Chloroprocaine 3% eye gel”, 1 entry
  • “Chloroprocaine ophthalmic gel 3%”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.